Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity
Journal
Vaccine
Journal Volume
39
Journal Issue
24
Pages
3259-3269
Date Issued
2021
Author(s)
Abstract
Background: Respiratory syncytial virus (RSV) is an important viral pathogen responsible for severe infection of the lower respiratory tract in children under the age of 5 years. No vaccines against RSV are currently in clinical use. Vaccine-associated en
Subjects
Adjuvant; HBc antigen; Mucosal immunity; RSV; Virus-like particle
SDGs
Other Subjects
core protein; gamma interferon; immunoglobulin G1; immunoglobulin G2a; respiratory syncytial virus vaccine; virus like particle vaccine; respiratory syncytial virus vaccine; virus antibody; virus fusion protein; amino acid sequence; animal experiment; ani
Publisher
Elsevier Ltd
Type
journal article